Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Tokyo, Japan.
Metrics to compare | 4889 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4889PeersSector | |
---|---|---|---|---|
P/E Ratio | 329.7x | 11.1x | −0.7x | |
PEG Ratio | 2.72 | 0.06 | 0.00 | |
Price/Book | 12.6x | 1.4x | 2.6x | |
Price / LTM Sales | 203.6x | 1.6x | 3.4x | |
Upside (Analyst Target) | - | 0.7% | 36.2% | |
Fair Value Upside | Unlock | 7.6% | 4.1% | Unlock |